Stroke Prevention in Atrial Fibrillation


Despite the evidence-based guidelines for the management of atrial fibrillation (AF), serious gaps continue to exist between clinical knowledge and practice, leaving patients at risk for disabling strokes. It is estimated that up to 67% of AF-related strokes are preventable. The significant increase in mortality and functional impairment is even more alarming, compared to non-AF strokes.


Updated AF treatment guidelines recommend new oral anticoagulants (NOACs) over warfarin for stroke prevention except, in patients with moderate to severe mitral stenosis or a mechanical heart valve. Based on some recent trials, NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with AF and an additional risk factor for stroke. Reversal agents are now also available for NOACs in patients for severe bleeding or emergency procedures.


With the increased utilization of NOACs, it is critical for the clinician to understand the clinical and practical usage of these agents in diverse patient populations and clinical situations.

Close X
Other videos you might like

Recent Videos


ESC 23: The NOAH-AFNET 6 Trial

Paulus Kirchhof,

Watch time: 3m 42s

Video Series

ESC 23: Hot Line & Late-breaking Science Video Collection

Yan Yan, Gilles Montalescot, Mathieu Kerneis, et al

Watch time: 5h 59m 38s (60 videos)


RIO 2022 – Six-month Case Retrospectives: In Full

Richard Schilling, KR Julian Chun, Devi Nair, et al

Watch time: 50m 43s


A Conversation with Dr Yoo

Dale Yoo,

Watch time: 20m 36s

Video Series

New Insights in LAAC Imaging: WATCHMAN TruPlan

Sergio Berti, Xavier Iriart, Xavier Millan, et al

Watch time: 1h 20m 28s (4 videos)

Video Series

RIO 2022 – Full Programme: On-Demand

KR Julian Chun, Boris Schmidt, Devi Nair, et al

Watch time: 17h 56m 35s (25 videos)